{"analyses":[{"groupDescription":"Fed versus Fasted","groupIds":["OG000"],"nonInferiorityType":"OTHER","pValue":"0.0441","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"Fed versus Fasted","groupIds":["OG001"],"nonInferiorityType":"OTHER","pValue":"0.4092","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"Fed versus Fasted","groupIds":["OG002"],"nonInferiorityType":"OTHER","pValue":"0.7748","statisticalMethod":"Wilcoxon (Mann-Whitney)"},{"groupDescription":"Fed versus Fasted","groupIds":["OG003"],"nonInferiorityType":"OTHER","pValue":"0.1948","statisticalMethod":"Wilcoxon (Mann-Whitney)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.0","upperLimit":"4.0","value":"2.0"},{"groupId":"OG001","lowerLimit":"2.0","upperLimit":"4.3","value":"4.0"},{"groupId":"OG002","lowerLimit":"2.1","upperLimit":"5.9","value":"4.0"},{"groupId":"OG003","lowerLimit":"1.9","upperLimit":"4.2","value":"2.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"title":"Fasted"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.9","upperLimit":"7.2","value":"4.0"},{"groupId":"OG001","lowerLimit":"4.0","upperLimit":"6.1","value":"4.0"},{"groupId":"OG002","lowerLimit":"3.8","upperLimit":"6.0","value":"4.0"},{"groupId":"OG003","lowerLimit":"4.0","upperLimit":"6.2","value":"4.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"3"}],"units":"Participants"}],"title":"Fed"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"description":"tmax was defined as the time of the maximum observed concentration of INCB001158.","dispersionType":"Full Range","groups":[{"description":"INCB001158 was administered orally at 50 milligrams (mg) twice daily (BID) in participants with advanced/metastatic solid tumors.","id":"OG000","title":"Part 1A: INCB001158 50 mg"},{"description":"INCB001158 was administered orally at 75 mg BID in participants with advanced/metastatic solid tumors.","id":"OG001","title":"Part 1A: INCB001158 75 mg"},{"description":"INCB001158 was administered orally at 100 mg BID in participants with advanced/metastatic solid tumors.","id":"OG002","title":"Part 1A: INCB001158 100 mg"},{"description":"INCB001158 was administered orally at 150 mg BID in participants with advanced/metastatic solid tumors.","id":"OG003","title":"Part 1A: INCB001158 150 mg"}],"paramType":"MEDIAN","populationDescription":"PK Population. Only participants with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"Fasted: Cycle 1 Day 15: predose; 0.5, 1, 2, 4, 6, 8, and 12 hours post-dose. Fed: Cycle 2 Day 8: predose; 0.5, 1, 2, 4, 6, and 8 hours post-dose","title":"Tmax of INCB001158 in the Fed and Fasted States Following Multiple Doses for Part 1A to Assess the Effect of Food","type":"SECONDARY","unitOfMeasure":"hours"}